Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony- stimulating factor

Nemunaitis, John; Shannon-Dorcy, Kathleen; Appelbaum, FR; Jd, Meyers; Owens, Ada; Day, Richard O.; Ando, Dale; O’Neill, Catherine; Buckner, Dean; Singer, Jack W.

doi:10.1182/blood.v82.5.1422.bloodjournal8251422

Cited by 24 publications

(26 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a small non-comparative study, administration of GM-CSF was associated with a complete or partial response in six of eight neutropenic patients with documented IFI (Bodey et al, 1994). The survival of bone marrow transplant patients with invasive candidiasis and a Karnofsky score >20% who received recombinant human M-CSF as adjunctive therapy, was significantly higher compared to historical controls (Nemunaitis et al, 1993). In a non-comparative pilot study of 11 acquired immunodeficiency syndrome (AIDS) patients with fluconazole-refractory oropharyngeal candidiasis, adjunctive treatment with GM-CSF (sargramostim) appeared to exert a beneficial effect (Vazquez et al, 2000).…”

Section: Clinical Evidence Of Cytokine Use In the Treatment Or Prevenmentioning

confidence: 91%

Cytokines and fungal infections

Antachopoulos¹,

Roilides²

2005

Br J Haematol

108

View full text Add to dashboard Cite

Summary The very poor outcome of invasive fungal infections (IFI) in patients with haematological malignancies or recipients of haematopoietic stem cell transplantation is largely attributed to their compromised host defence mechanisms. The restoration or augmentation of immune responses in these patients is now considered as one of the cornerstones of effective antifungal therapy. Major advances in the field of experimental immunology have provided insight on the important regulatory role of cytokines in both innate and adaptive immunity to fungal pathogens. Preclinical studies have convincingly demonstrated that immunomodulation with cytokines can enhance the antifungal activity of neutrophils and monocytes/macrophages as well as upregulate protective T‐helper type 1 adaptive immune responses. Evidence on the clinical use of cytokines in immunocompromised hosts with IFI is, however, still scant and inconclusive. The present review summarizes experimental and clinical data on the role of cytokines in the immune response to fungal pathogens and on their potential use for prevention or treatment of fungal infections. Implications for future research are also briefly discussed.

show abstract

Section: Clinical Evidence Of Cytokine Use In the Treatment Or Prevenmentioning

confidence: 91%

Cytokines and fungal infections

Antachopoulos¹,

Roilides²

2005

Br J Haematol

108

View full text Add to dashboard Cite

show abstract

“…In clinical trials, Nemunaitis et al [22,23] demonstrated that the combined use of M-CSF with standard anti-fungal treatment in patients with invasive fungal infections after bone marrow transplantation resulted in an improvement of the survival rate compared with the control. Ohno et al [24] reported that the administration of M-CSF signi®cantly reduced the incidence and duration of febrile neutropenia during the intensive consolidation therapy, and shortened the period required to complete three courses of consolidation chemotherapy in acute myelogenous leukaemia.…”

mentioning

confidence: 99%

Effects of macrophage colony-stimulating factor (M-CSF) on anti-fungal activity of mononuclear phagocytes againstTrichosporon asahii

Sasaki

Tashiro

Kuroki

et al. 2000

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Trichosporon asahii is an emerging opportunistic pathogen in immunocompromised patients. Little is known about the mechanisms of host defence against T. asahii. We investigated the fungicidal activity of human peripheral blood monocytes and murine peritoneal macrophages against T. asahii isolates, and the effects of M-CSF on the anti-fungal activity of mononuclear phagocytes. We also established a neutropenic mouse model of disseminated trichosporonosis with T. asahii. M-CSF enhanced the phagocytic fungicidal activity of mononuclear cells, and infected mice treated with human M-CSF at 10 x 106 U/kg showed a significant improvement in survival rate, with fewer fungal colony counts in the lung compared with control mice. Mice treated with human M-CSF showed higher concentrations of tumour necrosis factor-alpha (TNF-alpha) in the lung and plasma compared with control mice. The survival rate was significantly reduced in mice treated with anti-mouse TNF-alpha. Our results showed that M-CSF enhanced the fungicidal activity of mononuclear phagocytes partly by production of TNF-alpha, and suggest that the administration of M-CSF to patients with disseminated trichosporonosis may be a useful adjunct to conventional anti-microbial therapy and prophylaxis.

show abstract

“…34) In addition, a protective effect of M-CSF against fungal infection via monocytes was reported in vitro and in vivo. [35][36][37][38][39] In summary, the present findings suggest that granulocyte function should be improved to prevent infection after chemotherapy. Administration of M-CSF is effective for preventing the dysfunction of neutrophils, resulting in the prevention of febrile neutropenia following chemotherapy.…”

Section: Discussionmentioning

confidence: 88%

Macrophage Colony‐stimulating Factor Prevents Febrile Neutropenia Induced by Chemotherapy

Hidaka

Fujimura

Sakai

et al. 2001

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

There are very few studies describing the preventive effect of macrophage colony-stimulating factor (M-CSF/CSF-1) on chemotherapy-induced infection. In this study, we evaluated the changes in superoxide anion production by granulocytes before and after chemotherapy in ovarian cancer patients and investigated the preventive effect of M-CSF on chemotherapy-induced febrile neutropenia. Three courses of chemotherapy [paclitaxel 180 mg/m 2 and carboplatin (area under the curve; AUC 5)] were administered to 32 ovarian cancer patients, and seven patients presented febrile neutropenia. In the 25 afebrile patients, the percentage of superoxide anion production by granulocytes was significantly decreased from 86.5 ± ± ± ±7.7 (%) to 75.1 ± ± ± ±8.8 (%) at day 7 and 71.0 ± ± ± ±6.3(%) at day 14 without administration of CSF. However, in the patients who presented febrile neutropenia, it was more severely decreased from 86.8 ± ± ± ±6.8 (%) to 60.0± ± ± ±9.9 (%) at day 7 and 56.8 ± ± ± ±5.0 (%) at day 14 without administration of CSF. When M-CSF was administered to all patients in the next course with the same dose of chemotherapy, the incidence of febrile neutropenia was significantly decreased (P = = = =0.0195), and the duration of fever ( ≥ ≥ ≥ ≥38.0°C) and high serum C-reactive protein (CRP) ( ≥ ≥ ≥ ≥2.0 mg/dl) were also significantly shortened (P = = = =0.0023, P = = = =0.0051). Moreover, in these M-CSF-treated patients, the percentage of superoxide anion production by granulocytes was maintained at the level before chemotherapy. These findings indicate that severe impairment of granulocyte function leads to febrile neutropenia, and that M-CSF reduces the incidence of febrile neutropenia by maintaining or improving granulocyte function.

show abstract

Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony- stimulating factor

Cited by 24 publications

References 0 publications

Cytokines and fungal infections

Cytokines and fungal infections

Effects of macrophage colony-stimulating factor (M-CSF) on anti-fungal activity of mononuclear phagocytes againstTrichosporon asahii

Macrophage Colony‐stimulating Factor Prevents Febrile Neutropenia Induced by Chemotherapy

Contact Info

Product

Resources

About